Immunohistochemistry
- Sample Type
- Tissue Biopsy
- Fasting
- No
- Unit
- Qualitative/Score
Function
Immunohistochemistry (IHC) is a laboratory technique used to visualize the distribution and localization of specific proteins (antigens) within a tissue section. By using antibodies that bind specifically to these proteins, and tagging those antibodies with a visible color or fluorescent dye, pathologists can see exactly which cells are expressing which markers under a microscope.
Why it is Ordered
IHC is the gold standard for characterizing tumors. When a biopsy is taken, a standard stain (H&E) shows what the cells look like, but IHC tells the pathologist what the cells are. It is used to determine if a cancer is a carcinoma, sarcoma, or lymphoma, and to identify the primary site of a cancer that has spread (metastasis). It is also used to test for specific 'targets' like HER2 in breast cancer to see if certain drugs will work.
Associated Conditions
- Cancer Subtyping: Distinguishing between different types of lung or breast cancer.
- Predictive Markers: Checking for ER/PR (Estrogen/Progesterone) receptors in breast tissue.
- Infectious Disease: Detecting viral proteins (like CMV or HPV) directly within tissue cells.
- Lynch Syndrome Screening: Testing for DNA mismatch repair (MMR) proteins in colon cancer specimens.
Why Context Matters
IHC is highly sensitive to how the tissue was handled. The time it took to place the sample in fixative (cold ischemic time) and the duration of fixation can 'mask' antigens, leading to false-negative results. Furthermore, the 'scoring' of IHC (e.g., 1+ vs 2+ for HER2) involves human interpretation, which can vary between pathologists. A second opinion from a specialized center is often recommended for borderline results.
Lab ranges are statistical averages, not biological laws. "Normal" for a 20-year-old male isn't normal for a 60-year-old female.
Clinical References
Source-of-truth databases and clinical guidelines for Immunohistochemistry:
Official Sources
- Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology - PubMedpubmed.ncbi.nlm.nih.gov
- Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology - PubMedpubmed.ncbi.nlm.nih.gov
Research & Guidelines
- PubMed: Immunohistochemistry Clinical GuidelinesNCBI / PubMed
Related Indicators
Medically Reviewed by Dr. Binoy Babu, MBBS
Board Certified Doctor • 10+ Years Clinical Experience
Dr. Babu is a practicing physician dedicated to empowering patients with clear, actionable medical information. He founded 2opi to bridge the gap between complex lab reports and patient understanding, ensuring everyone has access to a reliable second opinion.
Get Notified When Dr. Babu Is Available